文献速递糖尿病

血糖降低方案比较效果研究(GRADE)中补救胰岛素的使用情况

The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
PubMed 文献 · Diabetes Care · 2024-01-01

GRADE研究纳入病程<10年、基线A1C 6.8%-8.5%且单用二甲双胍的2型糖尿病患者5047例,随机接受甘精胰岛素U-100、格列美脲、利拉鲁肽或西格列汀治疗并每季度随访平均5年。近半数(2387例,47.3%)达到补救胰岛素阈值;非甘精胰岛素组69%加用补救甘精胰岛素(39%在6周内),甘精胰岛素组44%加用补救门冬胰岛素(19%在6周内)。A1C越高越倾向于加用补救胰岛素,不想用胰岛素和想先改变生活方式是延迟加用的常见原因。

要点

  • GRADE研究中47.3%(2387例)的2型糖尿病患者达到补救胰岛素启用阈值。
  • 非甘精胰岛素组69%加用补救甘精胰岛素,其中39%在6周内加用。
  • 甘精胰岛素组44%加用补救门冬胰岛素(19%在6周内),非甘精胰岛素组30%(14%在6周内)。

核心结论

  • 需要时补救甘精胰岛素的使用比例高于补救门冬胰岛素,且A1C越高补救胰岛素使用越多。
  • 想用非胰岛素策略改善血糖是报告的常见原因,但多种因素可能共同导致未使用补救胰岛素。
  • 这些发现凸显了即便在临床试验中,用胰岛素强化2型糖尿病治疗仍持续面临挑战。

研究设计与样本

  • GRADE研究将病程<10年、基线A1C 6.8%-8.5%且单用二甲双胍的2型糖尿病患者5047例随机分配至甘精胰岛素U-100、格列美脲、利拉鲁肽或西格列汀组,每季度随访平均5年。
  • 补救胰岛素(甘精胰岛素或门冬胰岛素)应在确认A1C>7.5%后6周内启动。
  • 延迟补救胰岛素的原因由工作人员完成的调查问卷报告。

主要发现

  • GRADE参与者中近半数(2387例,47.3%)达到补救胰岛素阈值。
  • 分配至格列美脲、利拉鲁肽或西格列汀的参与者中,69%加用补救甘精胰岛素(39%在6周内)。
  • 甘精胰岛素组44%加用补救门冬胰岛素(19%在6周内),非甘精胰岛素组30%加用(14%在6周内)。
  • 较高的A1C值与加用补救胰岛素相关。
  • 未在6周内加用补救胰岛素的最常见原因包括打算改变健康行为(饮食/生活方式、坚持当前治疗)和不想使用胰岛素。

关键数值与推荐

  • 补救胰岛素启动阈值:确认A1C>7.5%后6周内。
  • 非甘精胰岛素组补救甘精胰岛素使用率69%(6周内39%)。
  • 甘精胰岛素组补救门冬胰岛素使用率44%(6周内19%),非甘精胰岛素组30%(6周内14%)。
  • 达到补救胰岛素阈值者2387例(47.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe rescue insulin use and associated factors in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). RESEARCH DESIGN AND METHODS: GRADE participants (type 2 diabetes duration <10 years, baseline A1C 6.8%-8.5% on metformin monotherapy, N = 5,047) were randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin and followed quarterly for a mean of 5 years. Rescue insulin (glargine or aspart) was to be started within 6 weeks of A1C >7.5%, confirmed. Reasons for delaying rescue insulin were reported by staff-completed survey. RESULTS: Nearly one-half of GRADE participants (N = 2,387 [47.3%]) met the threshold for rescue insulin. Among participants assigned to glimepiride, liraglutide, or sitagliptin, rescue glargine was added by 69% (39% within 6 weeks). Rescue aspart was added by 44% of glargine-assigned participants (19% within 6 weeks) and by 30% of non-glargine-assigned participants (14% within 6 weeks). Higher A1C values were associated with adding rescue insulin. Intention to change health behaviors (diet/lifestyle, adherence to current treatment) and not wanting to take insulin were among the most common reasons reported for not adding rescue insulin within 6 weeks. CONCLUSIONS: Proportionately, rescue glargine, when required, was more often used than rescue aspart, and higher A1C values were associated with greater rescue insulin use. Wanting to use noninsulin strategies to improve glycemia was commonly reported, although multiple factors likely contributed to not using rescue insulin. These findings highlight the persistent challenge of intensifying type 2 diabetes treatment with insulin, even in a clinical trial.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Hollander PA, Krause-Steinrauf H, Butera NM, et al. The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024. PMID: 37756542. doi:10.2337/dc23-0516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。